Integra LifeSciences Reports Preliminary Q3 Results, Lowers Full-Year Guidance; Shares Fall 11% Pre-Bell

08:42 AM EDT, 10/02/2026 (MT Newswires) -- Integra LifeSciences (IART) shares fell 11% in Friday's premarket session after it reported preliminary Q3 adjusted earnings of $0.55 to $0.59 per diluted share. The company expects revenue for the quarter ended Sept. 30 of $410 million to $412 million. Analysts surveyed by FactSet expect $416.3 million. For full-year 2026, the company expects adjusted EPS of $2.30 to $2.40 on revenue of $1.63 billion to $1.65 billion, down from previous guidance of $2.40 to $2.50 on revenue of $1.65 billion to $1.70 billion. Analysts surveyed by FactSet expect adjusted EPS of $2.45 and revenue of $1.67 billion.